Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer
January 29, 2020 13:00 ET
|
Onxeo SA
PARIS, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo to Present Next-Generation PARP Inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020
January 28, 2020 11:45 ET
|
Onxeo SA
PARIS, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Publishes Shareholder Newsletter
January 20, 2020 15:19 ET
|
Onxeo SA
PARIS, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of...
Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors
October 27, 2016 12:02 ET
|
Onxeo SA
Combination with checkpoint inhibitors decreased tumor growth rate and prolonged
survival in syngeneic HCC mouse model
PARIS & COPENHAGEN, Denmark--(BUSINESS...
Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update
October 25, 2016 12:02 ET
|
Onxeo SA
· Clinical development plan in line with objectives
· Livatag® on track to deliver its next important milestone with 90% of
patients randomized
· €12.5m capital increase successfully...
Onxeo: Publication of Shareholder Letter
October 12, 2016 12:02 ET
|
Onxeo SA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized
in the development of orphan oncology therapeutics,...
Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
October 10, 2016 12:01 ET
|
Onxeo SA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), a biopharmaceutical company
specializing in the development of innovative drugs for the...
Onxeo Raises €12.5 Million through Capital Increase with US and European Investors
September 30, 2016 03:05 ET
|
Onxeo SA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News:
Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):
THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN,
OR...
Onxeo Launches Capital Increase
September 29, 2016 12:43 ET
|
Onxeo SA
THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN,
OR AUSTRALIA
THIS PRESS RELEASE IS NOT INTENDED AS AN OFFER AND IS FOR INFORMATION PURPOSES
ONLY
PARIS &...
Onxeo Announces First Outcomes of Livatag® Preclinical Plan
September 12, 2016 01:32 ET
|
Onxeo SA
· Livatag® Nanoformulation Leads to Increased Exposure and Preferential
Affinity for Liver, Supporting Current Relive Phase III Study Rationale
· Demonstrates Enhanced Effect in Combination with...